Skip to main content

Table 3 Summary of safety

From: Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications

 

Percentages (%)

Elevated aspartate aminotransferase

 Any grade

55.1

 Grade ≥ 3

18.4

Bilirubin elevation

 Any grade

56.0

 Grade ≥ 3

12.0

Hypothyroidism

 Any grade

41.4

 Grade ≥ 3

0

Anemia

 Any grade

26.4

 Grade ≥ 3

3.8

Proteinuria

 Any grade

52.6

 Grade ≥ 3

2.6